Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.…
Aclaris stock falls after atopic dermatitis trial fails
Aclaris Therapeutics (NASDAQ: ACRS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 69 employees.
The shares were at 3.440 USD on 20 November 2026, up 47.0% over 52 weeks. Its 52-week range is 2.100 USD to 6.530 USD: the price is 47.3% below the high and 63.8% above the low.
Its market capitalisation is 545.63M USD.
Aclaris Therapeutics reports return on equity of -63.0% and revenue down 55.1% year over year.
It holds more cash than debt, a net cash position of 112.58M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 11 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 9.818 USD is 185.4% above the current price. The next earnings report is expected on 25 February 2027.